Editas Medicine, Inc. (EDIT)
NASDAQ: EDIT · Real-Time Price · USD
1.770
-0.010 (-0.56%)
At close: Feb 11, 2026, 4:00 PM EST
1.800
+0.030 (1.69%)
After-hours: Feb 11, 2026, 7:45 PM EST
Editas Medicine Employees
Editas Medicine had 246 employees as of December 31, 2024. The number of employees decreased by 19 or -7.17% compared to the previous year.
Employees
246
Change (1Y)
-19
Growth (1Y)
-7.17%
Revenue / Employee
$188,549
Profits / Employee
-$812,337
Market Cap
172.79M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 246 | -19 | -7.17% |
| Dec 31, 2023 | 265 | 39 | 17.26% |
| Dec 31, 2022 | 226 | -38 | -14.39% |
| Dec 31, 2021 | 264 | 29 | 12.34% |
| Dec 31, 2020 | 235 | 27 | 12.98% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Molecular Partners AG | 153 |
| Prelude Therapeutics | 131 |
| C4 Therapeutics | 110 |
| Tenaya Therapeutics | 97 |
| Cartesian Therapeutics | 66 |
| Sol-Gel Technologies | 34 |
| Eledon Pharmaceuticals | 31 |
| Galectin Therapeutics | 15 |
EDIT News
- 23 days ago - Genflow Biosciences PLC Announces Directorate Change - Accesswire
- 3 months ago - Editas Medicine Announces Third Quarter 2025 Results and Business Updates - GlobeNewsWire
- 3 months ago - Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025 - GlobeNewsWire
- 4 months ago - Editas Medicine: Three Strikes And It's Out, Or Third Time's The Charm? - Seeking Alpha
- 4 months ago - Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress - GlobeNewsWire
- 4 months ago - Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences - GlobeNewsWire
- 5 months ago - Editas Medicine, Inc. - Special Call - Seeking Alpha
- 5 months ago - Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate - GlobeNewsWire